ethyl 2-methyl-5,6,7,8-tetrahydrocyclohexa[b]pyridine-3-carboxylate | 42997-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 2-methyl-5,6,7,8-tetrahydrocyclohexa[b]pyridine-3-carboxylate
• 英文别名: ethyl 2-methyl-5,6,7,8-tetrahydroquinoline-3-carboxylate；5,6,7,8-tetrahydro-2-methyl-3-quinolinecarboxylic acid ethyl ester；2-methyl-5,6,7,8-tetrahydro-quinoline-3-carboxylic acid ethyl ester；2-Methyl-5,6,7,8-tetrahydro-chinolin-3-carbonsaeure-aethylester
• CAS: 42997-51-3
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.283
• InChiKey: UJRJCIKLAHNRHA-UHFFFAOYSA-N

物化性质

• 熔点：
  228 °C (decomp)
• 沸点：
  158 °C(Press: 11 Torr)
• 密度：
  1.095±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-methyl-5,6,7,8-tetrahydrocyclohexa[b]pyridine-3-carboxylate 在 乙基溴化镁 、 乙酸酐 作用下， 反应 5.5h， 生成 2-Methyl-8-[1-phenyl-meth-(Z)-ylidene]-5,6,7,8-tetrahydro-quinoline-3-carboxylic acid (4-methoxy-phenyl)-amide
  参考文献：
  名称：

  Synthesis and reactions of 8-benzylidene-2-methyl-5,6,7,8-tetrahydroquinoline-3-carboxylic acid arylamides

  摘要：

  DOI：

  10.1007/bf00542781
• 作为产物：
  描述：

  Cyclohexanone-2-carbaldehyde 生成 ethyl 2-methyl-5,6,7,8-tetrahydrocyclohexa[b]pyridine-3-carboxylate
  参考文献：
  名称：

  Basu, Justus Liebigs Annalen der Chemie, 1937, vol. 530, p. 131,138

  摘要：

  DOI：

文献信息

• Cycloalka[b]pyridine-3-carbonylguanidine derivatives, process for producing the same, and drugs containing the same
  申请人：Toa Eiyo Ltd.

  公开号：US06258829B1

  公开（公告）日：2001-07-10

  This invention relates to a cycloalka[b]pyridine-3-carbonylguanidine derivative represented by the following general formula (1): and a salt thereof, which can provide a drug having sodium/proton (Na+/H+) exchange transport inhibitory action.

  这项发明涉及一种由以下一般式（1）表示的环烷基吡啶-3-羰基胍衍生物及其盐，该物质可以提供具有钠/质子（Na+/H+）交换转运抑制作用的药物。
• Catalytic co-cyclisation of α,ω-cyanoalkynes with alkynes: a versatile chemo- and regio-selective synthesis of 2,3-substituted 5,6,7,8-tetrahydroquinolines and other cycloalka[1,2-b]pyridines
  作者：David J. Brien、Alaric Naiman、K. Peter C. Vollhardt

  DOI：10.1039/c39820000133

  日期：——

  α,ω-Cyanoalkynes are catalytically cocylised with alkynes in the presence of dicarbonyl(cyclopentadiecyl)-cobalt to furnish [b]annuiated pyridines chemo- and regio-selectively.

  在二羰基（环戊二烯基）-钴的存在下，将α，ω-氰基炔烃与炔烃催化羰基化，以化学和区域选择性地提供[ b ]环氧化的吡啶。
• Mannich Bases as Enone Precursors for Water-Mediated Efficient Synthesis of 2,3,6-Trisubstituted Pyridines and 5,6,7,8-Tetrahydroquinolines
  作者：Essam Hamied Ahmed Hanashalshahaby、Canan Unaleroglu

  DOI：10.1021/acscombsci.5b00046

  日期：2015.6.8

  has been developed for water-mediated synthesis of 2,3,6-trisubstituted pyridines and 5,6,7,8-tetrahydroquinolines. The introduced method allows easy preparation of various polysubstituted pyridines and 5,6,7,8-tetrahydroquinolines via domino reaction of an enolizable ketone, ammonia and enones derived from different Mannich bases in mild reaction conditions. Montmorillonite K-10 promoted this one-pot

  已经开发出一种高效，区域选择性和环境友好的方法，用于水介导的2,3,6-三取代吡啶和5,6,7,8-四氢喹啉的合成。通过在温和的反应条件下，可烯化的酮，氨和衍生自不同曼尼希碱的烯酮的多米诺反应，所引入的方法可轻松制备各种多取代的吡啶和5,6,7,8-四氢喹啉。蒙脱石K-10促进了这种一锅三组分反应，并以良好的收率得到了新的和已知的2,3,6-三取代的吡啶和5,6,7,8-四氢喹啉。该反应方案在容易应用和环境友好的条件下，由市售起始原料构建多取代吡啶和5,6,7,8-四氢喹啉具有广泛的功能性。
• Use of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as
  申请人：The Upjohn Company

  公开号：US04576949A1

  公开（公告）日：1986-03-18

  The present invention also provides novel compositions of matter. In particular, the present invention provides novel 3-substituted compounds of formula I which are from among the selected 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines having use as inhibitors of the synthesis of leukotrienes and as inhibitors of the action of lipoxygenase in mammalian metabolism.

  本发明还提供了新的物质组合物。特别地，本发明提供了公式I的新型3-取代化合物，它们属于所选的5,6,7,8-四氢喹啉和5,6-二氢吡啶，具有作为哺乳动物代谢中白三烯合成抑制剂和脂氧合酶作用抑制剂的用途。
• 5,6,7,8-Tetrahydroquinolines and 5,6-dihydropyrindines and their therapeutic use
  申请人：THE UPJOHN COMPANY

  公开号：EP0161867A2

  公开（公告）日：1985-11-21

  Compounds (many of which are novel) of the formula wherein D is N or N-O; n is zero or 1; R1 is H, CI-4 alkyl, cyclopropyl or phenyl optionally substituted by one or two substituents independently selected from halogen, CF3, SCH3, phenyl, OCH3, OH, N02, NR3R4 (R3 is H, C1-4 alkyl, acyl or aroyl and R4 is H or C1-4 alkyl), 1-pyrrolidinyl, 1-piperidinyl, OCOCH3, OCOC6H5 and OSi-(CH3)2C(CH3)3; R2 is H, Ci-4 alkyl, COOR5 (R5 is H or C1-4 alkyl or a pharmaceutically-acceptable cation), CH20H, CHO, CH=CH--(CH2)d-R6 (d is 0, 1, 2 or 3 and R6 is CH20H, CH2CI or COOR5 in which R5 is as defined above) or CH2CH2(CH2)dR6 (d and R6 are as defined above); and in which X1 is optionally substituted phenyl as defined above, 2-furyl or 2-thienyl, X2 is optionally substituted phenyl as defined above, CO(CH2)3R7, CHOH(CH2)3R7 (R7 is H, OH, Cl or 2-morpholinyloxy), 2-furanyl, 2,3-dihydro-2-furyl, 2,3--dihydro-5-furyl or 2-furyl) and X3 is optionally substituted phenyl as defined above; and pharmaceutically-acceptable salts thereof. These compounds can have utility in therapy, e.g. for the curative or prophylactic treatment of allergy, asthma, chronic bronchitis, cystic fibrosis, psoriasis or inflammatory bowel diseases.

  式中的化合物（其中许多为新型化合物 其中 D 是 N 或 N-O； n 为 0 或 1； R1 是 H、CI-4 烷基、环丙基或苯基，可任选被一个或两个独立选自卤素、CF3、SCH3、苯基、OCH3、OH、N02、NR3R4（R3 是 H、C1-4 烷基、酰基或芳基，R4 是 H 或 C1-4 烷基）、1-吡咯烷基、1-哌啶基、OCOCH3、OCOC6H5 和 OSi-(CH3)2C(CH3)3 的取代基取代； R2 是 H、Ci-4 烷基、COOR5（R5 是 H 或 C1-4 烷基或药学上可接受的阳离子）、CH20H、CHO、CH=CH--(CH2)d-R6（d 是 0、1、2 或 3，R6 是 CH20H、CH2CI 或 COOR5，其中 R5 如上定义）或 CH2CH2(CH2)dR6（d 和 R6 如上定义）；和 其中 X1 是如上定义的任选取代的苯基、2-呋喃基或 2-噻吩基，X2 是如上定义的任选取代的苯基、CO(CH2)3R7、CHOH(CH2)3R7（R7 是 H、OH、Cl 或 2-吗啉基氧基）、2-呋喃基、2,3-二氢-2-呋喃基、2,3-二氢-5-呋喃基或 2-呋喃基），X3 是如上定义的任选取代的苯基；及其药学上可接受的盐类。 这些化合物可用于治疗，如治疗或预防过敏、哮喘、慢性支气管炎、囊性纤维化、牛皮癣或炎症性肠病。